{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:13:55Z","timestamp":1753892035384,"version":"3.41.2"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T00:00:00Z","timestamp":1678752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008890","name":"University of Dundee","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008890","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background\/Aims:<\/jats:bold> Statin intolerance leads to poor adherence to statin therapy, resulting in a failure to achieve desired cholesterol reduction and adverse outcomes. The <jats:italic>LILRB5<\/jats:italic> Asp247Gly genotype has been identified as being associated with statin intolerance and statin-induced myalgia. We conducted a randomized clinical trial to examine its role in immune response through T regulatory cell aggregation and in achieving cholesterol reduction targets.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> A double-blind, cross-over, recruit-by-genotype trial was undertaken. A total of 18 participants who had either the Asp247Asp (T\/T) genotype or the Gly247Gly (C\/C) genotype were recruited to the study. Participants were randomised to receive placebo or atorvastatin 80\u00a0mg daily for 28\u00a0days. Following a washout period of 3\u00a0weeks, they were then switched to the opposite treatment. Biochemical and immunological measurements as well as interviews were performed prior to and after both treatment periods. Within genotype group comparisons were performed using repeated measures Wilcoxon tests. Two-way repeated measures ANOVA with genotype and treatment as factors were used to compare changes in biochemical parameters between groups during placebo and atorvastatin periods.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Individuals with the Asp247Asp genotype had a greater increase in creatine kinase (CK) compared to those with Gly247Gly genotype in response to atorvastatin (<jats:italic>p<\/jats:italic> = 0.03). Those with Gly247Gly genotype had a mean non-HDL cholesterol reduction of 2.44 (95% CI:1.59 \u2013 3.29) mmol\/L while in Asp247Asp genotype group the mean reduction was 1.28 (95%CI: 0.48 \u2013 2.07) mmol\/L. The interaction between the genotype and atorvastatin treatment for total cholesterol (p = 0.007) and non-HDL cholesterol response was significant (p = 0.025). Immunological assessment showed no significant changes in aggregation of T regulatory cells by genotype.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> The Asp247Gly variant in <jats:italic>LILRB5<\/jats:italic>, previously associated with statin intolerance, was associated with differential increases in creatine kinase and total cholesterol and non-HDL cholesterol-lowering response to atorvastatin. Taken together, these results suggest that this variant could have utility in precision cardiovascular therapy.<\/jats:p>","DOI":"10.3389\/fphar.2023.1090010","type":"journal-article","created":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T05:20:55Z","timestamp":1678771255000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["The cholesterol-lowering effect of statins is modified by LILRB5 intolerance genotype: Results from a recruit-by-genotype clinical trial"],"prefix":"10.3389","volume":"14","author":[{"given":"Aleksi","family":"Tornio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margherita","family":"Bigossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moneeza K.","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gwen","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ala\u2019a","family":"Melhem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehul K.","family":"Chourasia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cyrielle","family":"Maroteau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Pola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel I.","family":"Chasman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander S. F.","family":"Doney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin N. A.","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/clpt.2014.121","article-title":"Phenotype standardization for statin-induced myotoxicity","volume":"96","author":"Alfirevic","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"B2","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3390\/ijms18010104","article-title":"Pharmacogenetic foundations of therapeutic efficacy and adverse events of statins","volume":"18","author":"Arrigoni","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1024\/0301-1526\/a000969","article-title":"Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease","volume":"50","author":"Belch","year":"2021","journal-title":"Vasa"},{"key":"B4","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.taap.2016.06.032","article-title":"Statin-induced myotoxicity is exacerbated by aging: A biophysical and molecular biology study in rats treated with atorvastatin","volume":"306","author":"Camerino","year":"2016","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"244293","DOI":"10.1101\/2020.08.10.244293","article-title":"The MRC IEU OpenGWAS data infrastructure","volume":"2020","author":"Elsworth","year":"2020","journal-title":"bioRxiv"},{"key":"B6","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/ni904","article-title":"Foxp3 programs the development and function of CD4+CD25+ regulatory T cells","volume":"4","author":"Fontenot","year":"2003","journal-title":"Nat. Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"S72","DOI":"10.1016\/j.jacl.2014.03.002","article-title":"An assessment by the statin intolerance panel: 2014 update","volume":"8","author":"Guyton","year":"2014","journal-title":"J. Clin. Lipidol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1093\/ije\/dyx140","article-title":"Cohort profile: Genetics of diabetes audit and research in Tayside Scotland (GoDARTS)","volume":"47","author":"Hebert","year":"2018","journal-title":"Int. J. Epidemiol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.immuni.2016.01.009","article-title":"Poor repair of skeletal muscle in aging mice reflects a defect in local, interleukin-33-dependent accumulation of regulatory T cells","volume":"44","author":"Kuswanto","year":"2016","journal-title":"Immunity"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3569","DOI":"10.1093\/eurheartj\/ehx467","article-title":"A common missense variant of LILRB5 is associated with statin intolerance and myalgia","volume":"38","author":"Siddiqui","year":"2017","journal-title":"Eur. Heart J."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e013351","DOI":"10.1136\/bmjopen-2016-013351","article-title":"Cohort profile: The scottish research register SHARE. A register of people interested in research participation linked to NHS data sets","volume":"7","author":"McKinstry","year":"2017","journal-title":"BMJ Open"},{"key":"B12","doi-asserted-by":"publisher","first-page":"713181","DOI":"10.3389\/fgene.2021.713181","article-title":"Common statin intolerance variants in ABCB1 and LILRB5 show synergistic effects on statin response: An observational study using electronic health records","volume":"12","author":"Melhem","year":"2021","journal-title":"Front. Genet."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e003503","DOI":"10.1161\/circgen.121.003503","article-title":"Pharmacogenomic study of statin-associated muscle symptoms in the ODYSSEY OUTCOMES trial","volume":"15","author":"Murphy","year":"2022","journal-title":"Circulation Genomic Precis. Med."},{"article-title":"Guidelines","volume-title":"Cardiovascular disease: Risk assessment and reduction, including lipid modification","year":"2016","key":"B14"},{"key":"B15","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jval.2015.06.002","article-title":"Impact of statin adherence on cardiovascular morbidity and all-cause mortality in the primary prevention of cardiovascular disease: A population-based cohort study in Finland","volume":"18","author":"Rannanheimo","year":"2015","journal-title":"Value Health"},{"key":"B16","doi-asserted-by":"publisher","first-page":"762506","DOI":"10.1155\/2015\/762506","article-title":"Statins increase the frequency of circulating CD4+ FOXP3+ regulatory T cells in healthy individuals","volume":"2015","author":"Rodriguez-Perea","year":"2015","journal-title":"J. Immunol. Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.2337\/dci22-0003","article-title":"Using data to improve the management of diabetes: The Tayside experience","volume":"45","author":"Siddiqui","year":"2022","journal-title":"Diabetes Care"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e001737","DOI":"10.1161\/CIRCGENETICS.117.001737","article-title":"CKM Glu83Gly is associated with blunted creatine kinase variation, but not with myalgia","volume":"10","author":"Siddiqui","year":"2017","journal-title":"Circ. Cardiovasc Genet."},{"key":"B18","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1093\/qjmed\/hcv215","article-title":"Common Creatine Kinase gene mutation results in falsely reassuring CK levels in muscle disorders","volume":"109","author":"Wallace","year":"2016","journal-title":"QJM"},{"key":"B19","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1161\/CIRCRESAHA.118.312782","article-title":"Statin toxicity","volume":"124","author":"Ward","year":"2019","journal-title":"Circ. Res."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1090010\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T05:20:58Z","timestamp":1678771258000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1090010\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,14]]},"references-count":20,"alternative-id":["10.3389\/fphar.2023.1090010"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1090010","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2023,3,14]]},"article-number":"1090010"}}